🇺🇸 FDA
Pipeline program

NBI-1117568

NBI-1117568-BPD2036

Phase 2 small_molecule active

Quick answer

NBI-1117568 for Bipolar I Disorder is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Bipolar I Disorder
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials